Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The company is advancing its proprietary antiviral compound MGX-0024. The firm offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. The company has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.
How did MGRX's recent EPS compare to expectations?
The most recent EPS for Mangoceuticals Inc is $, expectations of $.
How did Mangoceuticals Inc MGRX's revenue perform in the last quarter?
Mangoceuticals Inc revenue for the last quarter is $
What is the revenue estimate for Mangoceuticals Inc?
According to of Wall street analyst, the revenue estimate of Mangoceuticals Inc range from $ to $
What's the earning quality score for Mangoceuticals Inc?
Mangoceuticals Inc has a earning quality score of B-/28.684826. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Mangoceuticals Inc report earnings?
Mangoceuticals Inc next earnings report is expected in 2026-08-11
What are Mangoceuticals Inc's expected earnings?
Mangoceuticals Inc expected earnings is $, according to wall-street analysts.
Did Mangoceuticals Inc beat earnings expectations?
Mangoceuticals Inc recent earnings of $ expectations.